Overview of Current Treatment Landscape of ALK Inhibitors

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Jacob Sands, MD

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Tim Cortese

July 31st 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

July 23rd 2025

Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

Russ Conroy

July 22nd 2025

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

Related Content

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Jacob Sands, MD

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Tim Cortese

July 31st 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

July 23rd 2025

Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Russ Conroy

July 22nd 2025